StudyFinder
Search Results
1 Study Matches
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS
A randomized placebo-controlled study to evaluate the efficacy and safety of dapirolizumab pegol in study participants with moderately to severely active systemic lupus erythematosus
There is up to 15 visits over the course of 54 weeks. Lab samples will be collected, medication will be administered.
amount varies based on visits completed
Jamie Carter - at jcarter3@pennstatehealth.psu.edu or 717-531-0003, ext=283833
All
All
NCT04294667
STUDY00017186
Inclusion Criteria:
≥16 years of age≥40kg and ≤160kg
diagnosis of Systemic lupus erythematosus (SLE)
Exclusion Criteria:
pregnancy history of chronic alcohol or drug abuse
known history of allergic reaction to the drug
Arthritis & Rheumatic Diseases
Experimental drug compared to a placebo/”sugar pill”